These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

420 related articles for article (PubMed ID: 30818144)

  • 41. A Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type Tumors.
    Evans KW; Yuca E; Akcakanat A; Scott SM; Arango NP; Zheng X; Chen K; Tapia C; Tarco E; Eterovic AK; Black DM; Litton JK; Yap TA; Tripathy D; Mills GB; Meric-Bernstam F
    Clin Cancer Res; 2017 Nov; 23(21):6468-6477. PubMed ID: 29093017
    [No Abstract]   [Full Text] [Related]  

  • 42. Deep exploration of PARP inhibitors in breast cancer: monotherapy and combination therapy.
    Chen Z; Wang X; Li X; Zhou Y; Chen K
    J Int Med Res; 2021 Feb; 49(2):300060521991019. PubMed ID: 33541181
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Homologous recombination deficiency derived from whole-genome sequencing predicts platinum response in triple-negative breast cancers.
    Ter Brugge P; Moser SC; Bièche I; Kristel P; Ibadioune S; Eeckhoutte A; de Bruijn R; van der Burg E; Lutz C; Annunziato S; de Ruiter J; Masliah Planchon J; Vacher S; Courtois L; El-Botty R; Dahmani A; Montaudon E; Morisset L; Sourd L; Huguet L; Derrien H; Nemati F; Chateau-Joubert S; Larcher T; Salomon A; Decaudin D; Reyal F; Coussy F; Popova T; Wesseling J; Stern MH; Jonkers J; Marangoni E
    Nat Commun; 2023 Apr; 14(1):1958. PubMed ID: 37029129
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Homologous Recombination Deficiency and Platinum-Based Therapy Outcomes in Advanced Breast Cancer.
    Zhao EY; Shen Y; Pleasance E; Kasaian K; Leelakumari S; Jones M; Bose P; Ch'ng C; Reisle C; Eirew P; Corbett R; Mungall KL; Thiessen N; Ma Y; Schein JE; Mungall AJ; Zhao Y; Moore RA; Den Brok W; Wilson S; Villa D; Shenkier T; Lohrisch C; Chia S; Yip S; Gelmon K; Lim H; Renouf D; Sun S; Schrader KA; Young S; Bosdet I; Karsan A; Laskin J; Marra MA; Jones SJM
    Clin Cancer Res; 2017 Dec; 23(24):7521-7530. PubMed ID: 29246904
    [No Abstract]   [Full Text] [Related]  

  • 45. Prevalence of pathogenic BRCA1/2 germline mutations among 802 women with unilateral triple-negative breast cancer without family cancer history.
    Engel C; Rhiem K; Hahnen E; Loibl S; Weber KE; Seiler S; Zachariae S; Hauke J; Wappenschmidt B; Waha A; Blümcke B; Kiechle M; Meindl A; Niederacher D; Bartram CR; Speiser D; Schlegelberger B; Arnold N; Wieacker P; Leinert E; Gehrig A; Briest S; Kast K; Riess O; Emons G; Weber BHF; Engel J; Schmutzler RK;
    BMC Cancer; 2018 Mar; 18(1):265. PubMed ID: 29514593
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Update on the Treatment of Early-Stage Triple-Negative Breast Cancer.
    Sharma P
    Curr Treat Options Oncol; 2018 Apr; 19(5):22. PubMed ID: 29656345
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Homologous recombination deficiency (HRD) score in germline BRCA2- versus ATM-altered prostate cancer.
    Lotan TL; Kaur HB; Salles DC; Murali S; Schaeffer EM; Lanchbury JS; Isaacs WB; Brown R; Richardson AL; Cussenot O; Cancel-Tassin G; Timms KM; Antonarakis ES
    Mod Pathol; 2021 Jun; 34(6):1185-1193. PubMed ID: 33462368
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Impact of homologous recombination deficiency biomarkers on outcomes in patients with triple-negative breast cancer treated with adjuvant doxorubicin and cyclophosphamide (SWOG S9313).
    Sharma P; Barlow WE; Godwin AK; Pathak H; Isakova K; Williams D; Timms KM; Hartman AR; Wenstrup RJ; Linden HM; Tripathy D; Hortobagyi GN; Hayes DF
    Ann Oncol; 2018 Mar; 29(3):654-660. PubMed ID: 29293876
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The role of novel poly (ADP-ribose) inhibitors in the treatment of locally advanced and metastatic Her-2/neu negative breast cancer with inherited germline BRCA1/2 mutations. A review of the literature.
    Pop L; Suciu I; Ionescu O; Bacalbasa N; Ionescu P
    J Med Life; 2021; 14(1):17-20. PubMed ID: 33767780
    [TBL] [Abstract][Full Text] [Related]  

  • 50. BRCA1- and BRCA2-related mutations: therapeutic implications in ovarian cancer.
    Pothuri B
    Ann Oncol; 2013 Nov; 24 Suppl 8():viii22-viii27. PubMed ID: 24131965
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Neoadjuvant talazoparib in patients with germline BRCA1/2 mutation-positive, early-stage triple-negative breast cancer: exploration of tumor BRCA mutational status.
    Telli ML; Litton JK; Beck JT; Jones JM; Andersen J; Mina LA; Brig R; Danso M; Yuan Y; Symmans WF; Hopkins JF; Albacker LA; Abbattista A; Noonan K; Mata M; Laird AD; Blum JL
    Breast Cancer; 2024 Sep; 31(5):886-897. PubMed ID: 38869771
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Biallelic
    Wineland D; Le AN; Hausler R; Kelly G; Barrett E; Desai H; Wubbenhorst B; Pluta J; Bastian P; Symecko H; D'Andrea K; Doucette A; Gabriel P; Reiss KA; Nayak A; Feldman M; Domchek SM; Nathanson KL; Maxwell KN; ;
    JCO Precis Oncol; 2023 Aug; 7():e2300036. PubMed ID: 37535879
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Molecular Features and Functional Implications of Germline Variants in Triple-Negative Breast Cancer.
    Ma D; Chen SY; Ren JX; Pei YC; Jiang CW; Zhao S; Xiao Y; Xu XE; Liu GY; Hu X; Liang XZ; Yu KD; Li DQ; Jiang YZ; Shao ZM
    J Natl Cancer Inst; 2021 Jul; 113(7):884-892. PubMed ID: 33151324
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Detection of Molecular Signatures of Homologous Recombination Deficiency in Prostate Cancer with or without BRCA1/2 Mutations.
    Sztupinszki Z; Diossy M; Krzystanek M; Borcsok J; Pomerantz MM; Tisza V; Spisak S; Rusz O; Csabai I; Freedman ML; Szallasi Z
    Clin Cancer Res; 2020 Jun; 26(11):2673-2680. PubMed ID: 32071115
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Triple-negative breast cancer and poly(ADP-ribose) polymerase inhibitors.
    Park Y; Moriyama A; Kitahara T; Yoshida Y; Urita T; Kato R
    Anticancer Agents Med Chem; 2012 Jul; 12(6):672-7. PubMed ID: 22263793
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Association of tumor immune infiltration and prognosis with homologous recombination repair genes mutations in early triple-negative breast cancer.
    Wang Z; Li A; Lu Y; Han M; Ruan M; Wang C; Zhang X; Zhu C; Shen K; Dong L; Chen X
    Front Immunol; 2024; 15():1407837. PubMed ID: 39026672
    [TBL] [Abstract][Full Text] [Related]  

  • 57. BET proteins regulate homologous recombination-mediated DNA repair: BRCAness and implications for cancer therapy.
    Mio C; Gerratana L; Bolis M; Caponnetto F; Zanello A; Barbina M; Di Loreto C; Garattini E; Damante G; Puglisi F
    Int J Cancer; 2019 Feb; 144(4):755-766. PubMed ID: 30259975
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Guanosine diphosphate-mannose suppresses homologous recombination repair and potentiates antitumor immunity in triple-negative breast cancer.
    Ding JH; Xiao Y; Yang F; Song XQ; Xu Y; Ding XH; Ding R; Shao ZM; Di GH; Jiang YZ
    Sci Transl Med; 2024 Jan; 16(728):eadg7740. PubMed ID: 38170790
    [TBL] [Abstract][Full Text] [Related]  

  • 59. BRCAness and Prognosis in Triple-Negative Breast Cancer Patients Treated with Neoadjuvant Chemotherapy.
    Tanino H; Kosaka Y; Nishimiya H; Tanaka Y; Minatani N; Kikuchi M; Shida A; Waraya M; Katoh H; Enomoto T; Sengoku N; Kajita S; Hoffman RM; Watanabe M
    PLoS One; 2016; 11(12):e0165721. PubMed ID: 27935989
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Genomic Signatures Predict the Immunogenicity of BRCA-Deficient Breast Cancer.
    Kraya AA; Maxwell KN; Wubbenhorst B; Wenz BM; Pluta J; Rech AJ; Dorfman LM; Lunceford N; Barrett A; Mitra N; Morrissette JJD; Feldman M; Nayak A; Domchek SM; Vonderheide RH; Nathanson KL
    Clin Cancer Res; 2019 Jul; 25(14):4363-4374. PubMed ID: 30914433
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.